In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 55, No. 7 ( 2011-07), p. 3631-3634
Kurzfassung:
JNJ-Q2 is a broad-spectrum bactericidal fluoroquinolone with potent activity against Gram-positive and -negative pathogens. In this study, the in vitro activity of JNJ-Q2 was evaluated against 511 selected Staphylococcus aureus samples isolated in 2008-2009 from patients with acute bacterial skin and skin structure infections in the United States by using reference methodology. JNJ-Q2 was the most potent fluoroquinolone tested overall (MIC 50 and MIC 90 , 0.12 and 0.5 μg/ml, respectively) and against methicillin- and fluoroquinolone-resistant subgroups in direct comparisons to moxifloxacin, levofloxacin, and ciprofloxacin (each being ≥16-fold less potent than JNJ-Q2).
Materialart:
Online-Ressource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.00162-11
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2011
ZDB Id:
1496156-8
SSG:
12
SSG:
15,3
Permalink